Get in on Nutex Health Inc.’s (NUTX) buy-in window today!

Nutex Health Inc. (NASDAQ: NUTX) stock jumped 0.74% on Monday to $1.36 against a previous-day closing price of $1.35. With 1.24 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.51 million shares. During the session, the Health Information Services company that operates in wider Healthcare sector, reached to the highest price of $1.3750 whereas the lowest price it dropped to was $1.2101. The 52-week range on NUTX shows that it touched its highest point at $52.80 and its lowest point at $0.50 during that stretch. It currently has a 1-year price target of $3.00. Beta for the stock currently stands at 0.63.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of NUTX was down-trending over the past week, with a drop of -20.47%, but this was down by -30.96% over a month. Three-month performance surged to 109.39% while six-month performance fell -50.36%. The stock lost -71.49% in the past year, while it has lost -28.42% so far this year. A look at the trailing 12-month EPS for NUTX yields -0.74 with Next year EPS estimates of 0.00. For the next quarter, that number is -0.01. This implies an EPS growth rate of 68.20% for this year and 100.00% for next year.

Float and Shares Shorts:

At present, 649.58 million NUTX shares are outstanding with a float of 321.69 million shares on hand for trading. On Oct 13, 2022, short shares totaled 3.7 million, which was 0.57% higher than short shares on Sep 14, 2022. In addition to Dr. Thomas T. Vo M.B.A., M.D. as the firm’s Chairman & CEO, Dr. Warren Hosseinion M.D. serves as its Pres & Director.


Institutional Ownership:

Through their ownership of 1.13% of NUTX’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 41.53% of NUTX, in contrast to 1.65% held by mutual funds. Shares owned by individuals account for -0.37%. As the largest shareholder in NUTX with 0.23% of the stake, BlackRock Fund Advisors holds 1,464,540 shares worth 1,464,540. A second-largest stockholder of NUTX, Creative Planning LLC, holds 818,695 shares, controlling over 0.13% of the firm’s shares. Ergoteles LLC is the third largest shareholder in NUTX, holding 816,824 shares or 0.13% stake. With a 0.80% stake in NUTX, the iShares Russell 2000 ETF is the largest stakeholder. A total of 5,210,628 shares are owned by the mutual fund manager. The iShares Russell 2000 Growth ETF, which owns about 0.32% of NUTX stock, is the second-largest Mutual Fund holder. It holds 2,077,065 shares valued at 3.95 million. Vanguard Russell 2000 Index Fund holds 0.10% of the stake in NUTX, owning 637,216 shares worth 1.21 million.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for NUTX since 1 analysts follow the stock currently. There are 1 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With NUTX analysts setting a high price target of $3.00 and a low target of $3.00, the average target price over the next 12 months is $3.00. Based on these targets, NUTX could surge 120.59% to reach the target high and rise by 120.59% to reach the target low. Reaching the average price target will result in a growth of 120.59% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. Analysts have provided yearly estimates in a range of -$0.67 being high and -$0.67 being low. For NUTX, this leads to a yearly average estimate of -$0.67. Based on analyst estimates, the high estimate for the next quarter is -$0.01 and the low estimate is -$0.01. The average estimate for the next quarter is thus -$0.01.

Summary of Insider Activity:

Insiders traded NUTX stock several times over the past three months with 0 Buys and 2 Sells. In these transactions, 0 shares were bought while 169,378 shares were sold. The number of buy transactions has increased to 21 while that of sell transactions has risen to 3 over the past year. The total number of shares bought during that period was 857,888,317 while 272,266 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *